Mount Sinai Joins $5M Push to Remap the Fight Against Autoimmune Disease

NEW YORK, NY – July 21, 2026 – In a strategic move that signals a major shift in the war against chronic illness, the Icahn School of Medicine at Mount Sinai has been brought into an elite international research network with a $5 million gift from philanthropists Judith and Stewart Colton. The donation establishes the Colton Center for Autoimmunity, positioning Mount Sinai as the fifth pillar in a powerful consortium dedicated to dismantling the complexities of autoimmune diseases, which now affect an estimated 8-10% of the global population.

This isn't just another research grant. It's the expansion of a meticulously architected philanthropic model that connects top-tier academic institutions—NYU, Yale, the University of Pennsylvania, and Tel Aviv University—into a collaborative force. By adding Mount Sinai's formidable capabilities in immunology and data science, the Colton Consortium is amplifying its high-stakes bet: that by understanding the common biological roots of these disparate diseases, they can move beyond merely managing symptoms and begin to engineer cures.

The new center will be embedded within Mount Sinai’s Marc and Jennifer Lipschultz Precision Immunology Institute (PrIISM), a hub known for its success in applying cross-disease approaches to cancer and inflammation. This integration underscores a core strategic principle: the future of medicine lies not in siloed specialties, but in identifying and targeting the fundamental mechanisms that drive disease across the human body.

The Precision Mandate: A New Blueprint for a Growing Crisis

Autoimmune diseases represent one of modern medicine’s most vexing challenges. The category encompasses over 100 distinct conditions—from rheumatoid arthritis and lupus to multiple sclerosis and psoriasis—where the body’s own defense system turns against it. With global prevalence rates nearly doubling between 1990 and 2021, the crisis is escalating, yet patients often endure years of diagnostic delays and a trial-and-error journey through treatments that rely on broad immunosuppression, leaving them vulnerable to infection and other side effects.

The Colton Center’s mission is to tear up that playbook. The research is grounded in a paradigm-shifting insight: although these diseases attack different organs, many are driven by the same faulty immune pathways. As the center's newly appointed director, Dr. Shruti Naik, explained, this new approach is critical.

"This gift allows us to pursue science at the scale this challenge demands," said Dr. Naik, an Associate Professor of Immunology and Immunotherapy. "Autoimmune diseases have traditionally been studied as separate conditions, yet many are driven by shared immune mechanisms. By understanding what connects these diseases at their biological roots, we can move beyond managing symptoms and toward more precise, personalized approaches to prevention and treatment."

This is where Mount Sinai’s specific expertise becomes a force multiplier. PrIISM's Human Immune Monitoring Center, founded by the new center’s Co-Director Dr. Miriam Merad, is one of the world's most advanced facilities for deep immune profiling. Using cutting-edge single-cell technology and AI-enabled analytics, researchers can build massive datasets that map the intricate cellular behavior underlying disease. The goal is to identify autoimmune disorders before symptoms even appear, discover biomarkers that predict flare-ups, and ultimately tailor therapies to an individual’s unique immune profile.

A Consortium Forged by Personal Conviction

The strategic framework of the Colton Consortium is as innovative as its science, and it stems from a deeply personal source. Judith and Stewart Colton’s philanthropic journey began in 2001 after a family member’s struggle with an autoimmune condition exposed the frustrating gaps in diagnosis and treatment. This experience ignited a long-term commitment not just to fund research, but to change how it is conducted.

They established their first center at NYU Langone Health in 2014, building a model based on collaboration over competition. The strategy proved successful, leading to subsequent centers at Yale, the University of Pennsylvania, and Tel Aviv University. The network fosters data sharing, multidisciplinary projects, and rapid translation of findings into diagnostics and therapies—a stark contrast to the often-siloed nature of academic research.

Mount Sinai's inclusion is a testament to this vision. "Judith and Stewart Colton have built something remarkable—a consortium across institutions that is redefining how autoimmune disease is understood and treated," said Dr. Eric J. Nestler, Dean of the Icahn School of Medicine. "We are very honored to be part of the Colton Consortium. Their investment in our new Center reflects both extraordinary generosity and a deep appreciation of what it takes to transform scientific discovery into meaningful improvements in patient care and outcomes."

This network acts as a catalyst, pooling intellectual capital and resources to de-risk ambitious projects and accelerate progress. The consortium's director, Dr. John Wherry, noted the strategic value of this expansion. “We are thrilled to have Mount Sinai join the Colton Consortium, bringing expertise in autoimmunity and immune profiling that will complement existing work at the other four Colton centers,” he stated. “This expansion of the Consortium will further catalyze the impact of discovery science on diagnosis, treatment, and prevention of autoimmunity.”

Accelerating Discovery into Clinical Impact

For Mount Sinai, joining the consortium solidifies its position as a global nexus for immunological innovation. The institution is not merely a recipient of funds but an active partner expected to contribute its unique strengths to the collective mission. The leadership of Dr. Naik, who previously served as Associate Director of the Colton Center at NYU, provides invaluable continuity and a deep understanding of the consortium's collaborative ethos.

She is joined by Dr. Miriam Merad, a titan in the field who serves as Dean for Translational Research and Director of PrIISM. Dr. Merad’s role ensures that the center’s work is tightly integrated with Mount Sinai’s broader institutional strategy of rapidly moving discoveries from the lab bench to the patient bedside. Her vision is to create a seamless pipeline for innovation.

"Our goal is to connect every stage of discovery—from deep immune profiling and defining disease mechanisms to developing precision therapies and testing them in innovative clinical trials," said Dr. Merad. "Working closely with our Consortium partners, we aim to fundamentally change how autoimmune diseases are detected, treated, and ultimately prevented."